Mérieux Equity Partners
VC Fund
Lyon, France
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
- Total investments:
- 57
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries Mérieux Equity Partners invests in
Stages Mérieux Equity Partners invests in
Countries Mérieux Equity Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Series A
- $5.7M–$23M
- Series B
- $7.2M–$48M
- Private Equity
- $23M–$150M
Investment Focus
Industry
- Health Care 29 (51%)
- Biotechnology 23 (40%)
- Medical Device 13 (23%)
- Medical 12 (21%)
- Manufacturing 11 (19%)
Stage
- Series A 10 (18%)
- Private Equity 10 (18%)
- Series B 8 (14%)
- Series C 8 (14%)
- Venture - Series Unknown 6 (11%)
Country
- France 18 (32%)
- United States 11 (19%)
- Belgium 3 (5%)
- Switzerland 2 (4%)
- United Kingdom 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Francois Valencony
Managing Partner,/founder & Executive Officer; Managing Partner & Executive Officer
|
Managing Partner,/founder & Executive Officer; Managing Partner & Executive Officer | Total investments: 18 | Find email | |
Jean-Francois Billet
Senior Partner
|
Senior Partner | Total investments: 2 | Find email | |
Jean-Guillaume Lafay
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
Thierry Chignon
Senior Partner
|
Senior Partner | Total investments: 4 | Find email | |
Valerie Calenda
Managing Partner
|
Managing Partner | Total investments: 15 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
| Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs. | Private Equity / Mar 31, 2025 | ||
| CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M / Series B / Sep 10, 2024 | ||
| Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit. | $13M / Series A / Apr 09, 2024 | ||
| Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $5.7M / Series A / Nov 07, 2023 | ||
| Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies. | $15M / Series A / Sep 18, 2023 | ||
| TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $53.8M / Series D / May 23, 2023 | ||
| Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC). | $30.1M / Series A / Oct 14, 2022 | ||
| AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. | $29.9M / Seed / Aug 25, 2022 | ||
| Cairdac is a manufacturer of autonomous leadless pacing transcatheter system capable of powering the device with no battery-life limitation. | $18.8M / Series A / Mar 31, 2022 | ||
| See all 57 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mérieux Equity Partners invest in?
Mérieux Equity Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Private Equity stage. Most of the 57 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Mérieux Equity Partners's check size?
Mérieux Equity Partners typically joins rounds of $5.7M–$23M at Series A, $7.2M–$48M at Series B and $23M–$150M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mérieux Equity Partners participates in.
How do I contact Mérieux Equity Partners?
Public channels for Mérieux Equity Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mérieux Equity Partners?
The team at Mérieux Equity Partners includes Francois Valencony (Managing Partner,/founder & Executive Officer; Managing Partner & Executive Officer), Jean-Francois Billet (Senior Partner) and Jean-Guillaume Lafay (Operating Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
